Torrent Pharmaceuticals will engage with investors at two separate conferences scheduled in Mumbai during early June 2026. The company's representatives will participate in the BoFA 2026 India Conference and Citi's 2026 India Conference to discuss business performance and strategy.

The meetings are scheduled for June 3 and June 4, 2026, respectively. Both events will include group sessions as well as one-on-one interactions, providing a platform for detailed engagement with the investor community.

The schedule for these meetings is subject to change due to exigencies on the part of the company or the investors. The intimation was submitted to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investor Meet Schedule

Torrent Pharmaceuticals has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a 12% increase in consolidated net profit to ₹2,138 crore for the full fiscal year FY26, compared to ₹1,911 crore in the previous year. Total revenues for the year grew by 21% to ₹13,980 crore, up from ₹11,516 crore in FY25. This growth was driven by robust performance across key geographies, including India, the United States, and Brazil, alongside the initial integration of J.B. Chemicals & Pharmaceuticals (JB Pharma).

Q4 FY26 Highlights

In the fourth quarter of FY26, the company recorded total revenues of ₹4,197 crore, compared to ₹2,959 crore in the corresponding period of the previous year. Consolidated net profit for the quarter stood at ₹390 crore, against ₹498 crore in the year-ago period. This decline was attributed to exceptional items and acquisition-related costs associated with the JB Pharma integration. Excluding JB Pharma, the base business recorded revenue growth of 16% for the quarter.

Q4 FY26 Key Metrics

The following table summarises the key financial metrics for Q4 FY26 on a year-on-year basis:

Q4 FY26 Segment Revenue

The India segment led the growth with a 43% surge during the quarter. The following table presents the segment-wise revenue breakdown for Q4 FY26:

FY26 Revenue Summary

The company's revenue performance for the full fiscal year reflected strong growth across all major markets. The India segment contributed ₹7,645 crore, growing by 20%, while the United States and Brazil segments grew by 24% each to ₹1,363 crore and ₹1,362 crore respectively.

Dividend and Fundraising

The Board has recommended a final dividend of ₹9 per equity share for the fiscal year 2025-26, with Friday, May 29, 2026, fixed as the record date. An interim dividend of ₹29 per share was previously paid during the last quarter. Additionally, the Board has recommended enabling approval for the issuance of equity shares, including convertible bonds or debentures, through Qualified Institutional Placement (QIP) or other modes for an amount not exceeding ₹5,000 crores.

Conference Call Transcript

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the conference call with analysts and investors on the audited financial results for the quarter and year ended March 31, 2026, has been placed on the company's website.